Evidence map›Paper›PMID 38383349›Full record

ReviewNucleus (Austin, Tex.)2024

Nuclear pore dysfunction and disease: a complex opportunity.

Charlotte M Fare, Jeffrey D Rothstein

Open access · goldAbstract readReview
In one paragraph

Review in Nucleus (Austin, Tex.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Charlotte M FareDepartment of Neurology and Brain Science Institute, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0003-0394-6435
Jeffrey D RothsteinDepartment of Neurology and Brain Science Institute, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0003-2001-8470
Johns Hopkins University · US

Funding

Project 3: Neuropathology of the multi-proteinopathy of c9FTD/ALS.P01NS084974 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2014 to 2024
$17.6M
Nuclear and Glial Dysfunction in NeurodegenerationR35NS132179 · NINDS · JOHNS HOPKINS UNIVERSITY · PI Jeffrey D Rothstein · 2023 to 2026
$4.9M
Nuclear pore complex quality control in ALS/FTDR01NS122236 · NINDS · JOHNS HOPKINS UNIVERSITY · PI LUSK, CHARLES PATRICK, ROTHSTEIN, JEFFREY D · 2021 to 2025
$4.0M
Nuclear Pore Complex and as a Contributor to Tau Associated DementiaRF1AG062171 · NIA · JOHNS HOPKINS UNIVERSITY · PI PETRUCELLI, LEONARD, ROTHSTEIN, JEFFREY D · 2019 to 2019
$3.8M
NIA NIH HHS RF1 AG062171NINDS NIH HHS P01 NS084974NINDS NIH HHS R01 NS122236NINDS NIH HHS R35 NS132179
6 · The paper itself

Abstract

The separation of genetic material from bulk cytoplasm has enabled the evolution of increasingly complex organisms, allowing for the development of sophisticated forms of life. However, this complexity has created new categories of dysfunction, including those related to the movement of material between cellular compartments. In eukaryotic cells, nucleocytoplasmic trafficking is a fundamental biological process, and cumulative disruptions to nuclear integrity and nucleocytoplasmic transport are detrimental to cell survival. This is particularly true in post-mitotic neurons, where nuclear pore injury and errors to nucleocytoplasmic trafficking are strongly associated with neurodegenerative disease. In this review, we summarize the current understanding of nuclear pore biology in physiological and pathological contexts and discuss potential therapeutic approaches for addressing nuclear pore injury and dysfunctional nucleocytoplasmic transport.

Indexed as

Neurodegenerative DiseasesNuclear PoreActive Transport, Cell NucleusCell NucleusHumansNuclear Pore Complex ProteinsNuclear Pore Complex ProteinsNeurodegenerative diseasenuclear envelopenuclear pore complexnucleocytoplasmic transportnucleoporintherapeutics

Identifiers

PMID38383349
PMCPMC10883112
OpenAlexW4392057407

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.